期刊文献+

高龄心房颤动患者导管消融围术期不同抗凝方案的对比观察 被引量:11

Feasibility and safety of three periprocedure anticoagulation therapy in patients over 75 years undergoing radiofrequency ablation for atrial fibrillation
下载PDF
导出
摘要 目的观察大于75岁的高龄心房颤动(房颤)患者围导管消融期三种抗凝方案的安全有效性。方法选取2011年7月到2013年12月行房颤导管消融治疗的高龄(>75岁)房颤患者85例,术前常规华法林抗凝后经食管超声检查排除左心耳血栓,分为三组:传统抗凝组30例,消融前停用华法林,以低分子肝素桥接,术中用普通肝素抗凝,术后桥接低分子肝素联合华法林过渡到单用华法林;华法林持续使用组32例,围消融期正常使用华法林,术中使用普通肝素抗凝;新型口服抗凝药物组23例(达比加群组12例,利伐沙班组11例),术前、术中同传统抗凝组,术后4 h开始服用达比加群或利伐沙班抗凝。比较三组抗凝方案围术期到术后3个月的出血和栓塞事件发生率及其他并发症。结果传统抗凝组住院期间新发脑梗死1例,下肢血肿7例,假性动脉瘤1例,出院后3个月内内脏出血1例,小出血事件6例;华法林持续使用组院内下肢血肿4例,出院后3个月内小出血事件4例;新型口服抗凝药物院内下肢血肿2例,出院后无小出血事件。结论高龄房颤患者行导管消融治疗,总体安全有效。与传统抗凝治疗方案对比,持续使用华法林方案或采用新型口服抗凝药物能进一步降低出血并发症风险,并未增加血栓栓塞的风险。 Objective To observe the safety and efficacy of different periprocedural anticoagulation strategies in patients undergoing catheter ablation of atrial ifbrillation. Methods Eighty-five patients aged over 75 undergoing catheter ablation of atrial fibrillation from Jul 2011 to Nov 2013 were enrolled. They all took warfarin and transesophageal echocardiograms were performed to rule out left atrium appendage thrombus before ablation. They were divided into 3 groups. In Group 1 (30 cases), warfarin was stopped and bridged with low molecular weight heparin (LMWH) 3 days before procedure and LMWH bridging followed by warfarin alone after procedure. In Group 2 (32 cases), warfarin was continued during periprocedural period. In Group 3 (23 cases), Dabigatran or Rivaroxaban alone was used 4 hours after procedure respectively. Unfractionated heparin was used during procedure in all three groups. These three anticoagulation strategies were compared in bleeding, embolism events and other complications during 3-month follow-up. Results In Group 1, there were 1 new-onset ischemic stroke during hospitalization, 7 lower extremity hematomas, 1 subdural hemorrhage during 3-month follow-up and 6 minor bleeding events. In Group 2, there were 4 lower extremity hematomas and 4 minor bleeding events during 3-month follow-up. As for Group 3, only 2 lower extremity hematomas during hospitalization was observed in each without any minor bleeding events during follow-up. Conclusions Catheter ablation in elderly atrial ifbrillation patients was safe and effective in general. Compared with traditional anticoagulation strategy, continuing warfarin or novel oral anticoagulants could reduce bleeding complications without increasing thromboembolism risk.
出处 《中国介入心脏病学杂志》 2014年第4期220-224,共5页 Chinese Journal of Interventional Cardiology
关键词 心房颤动 导管消融 抗凝治疗 血栓栓塞 Atrial ifbrillation Catheter ablation Anticoagulation therapy Thromboembolism
  • 相关文献

参考文献24

  • 1Kopecky SL, Gersh B J, McGoon MD, et al. The natural history, of lone atrial fibrillation. A population-based study over three decades. N Engl J Med, 1987, 317:669-674.
  • 2Haegeli LM, Duru F. Management of Patients with Atrial Fibrillation: Specific Considerations for the Old Age. Cardiol Res Pract, 2011, 2011:1-8.
  • 3王新华,刘旭,顾佳宁,周立,高东升,胡伟,邱建华.环肺静脉消融电隔离治疗持续性心房颤动的疗效观察[J].中国介入心脏病学杂志,2006,14(3):147-151. 被引量:20
  • 4施海峰,刘旭,王新华,顾佳宁,孙育民,周立,胡伟,方唯一.导管消融治疗慢性心房颤动两种消融策略对比研究[J].中国介入心脏病学杂志,2007,15(3):133-138. 被引量:7
  • 5Gautam S, John RM, Stevenson WG, et al. Effect of therapeutic INR on activated clotting times, heparin dosage, and bleeding risk during ablation of atrial fibrillation. J Cardiovasc Electrophysiol, 2011, 22:248-254.
  • 6Benjamin EJ, Wolf PA, D' Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation, 19981 98: 946-952.
  • 7Thrall G, Lane D, Carroll D, et al. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med, 2006, 119: 448, e1-9.
  • 8Noheria A, Kumar A, Wylie JV Jr, et al. Catheter ablation vs antiarrhythmic drug therapy for atrial fibrillation: a systematic review. Arch Intern Med, 2008, 168: 581-586.
  • 9Oral H, Pappone C, Chugh A, et al. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med, 2006, 354: 934-941.
  • 10Bunch T J, May HT, Bair TL, et al. Atrial fibrillation ablation patients have long-term stroke rates similar to patients without atrial fibrillation regardless of CHADS2 score. Heart Rhythm, 2013, 10: 1272-1277.

二级参考文献98

  • 1刘旭,王新华,马建伟,顾佳宁,邱建华.环状电极在Ensite/NavX指导下的心房颤动环肺静脉消融术中的应用[J].中国介入心脏病学杂志,2005,13(4):212-214. 被引量:7
  • 2马长生,刘旭,董建增,喻荣辉,王新华,刘兴鹏,施海峰,龙德勇,方冬平,胡福莉,汤日波.环肺静脉线性消融治疗慢性心房颤动疗效分析[J].中华医学杂志,2006,86(16):1111-1114. 被引量:4
  • 3王新华,刘旭,顾佳宁,周立,高东升,胡伟,邱建华.环肺静脉消融电隔离治疗持续性心房颤动的疗效观察[J].中国介入心脏病学杂志,2006,14(3):147-151. 被引量:20
  • 4Wolf PA,Abbott RD,Kannel WB.Atrial fibrillation as an independent risk factor for stroke:the Framingham Study.Stroke,1991,22:983-988.
  • 5Fuster V,Ryden LE,Cannom DS,et al.ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation:a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of canliology committee for practice guidelines(Writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation):developed in collaboration with the European heart Rhythm association and the heart Rhythm society.Circulation,2006,1 14:e257-354.
  • 6Petersen P,Boysen G,Godtfredsen J,et al.Placebocontrolled.randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation.The Copenhagen AFASAK study.Lancet,1989,1:175-179.
  • 7Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia.The European atrial fibrillation trial study group.N Engl J Med,1995,333:5-10.
  • 8Van Walraven C,Hart RG,Singer DE,et al.Oral anticoagulants vs aspitin in nonvalvular atrial fibrillation:an individual patient meta-analysis.JAMA,2002,288:2441-2448.
  • 9Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation:stroke prevention in atrial fibrillation Ⅱ study.Lancet,1994,343:687-691.
  • 10Kamath S,Blann AD,Chin BS,et al.A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation.J Am Coll Cardiol,2002,40:484-490.

共引文献67

同被引文献131

  • 1路新华,郑智慧,马瑛,石英,董悦生,任晓,穆栋,张华,贺建功.微生物来源的Xa因子抑制剂F02-2172的研究[J].中国抗生素杂志,2007,32(5):277-279. 被引量:9
  • 2Cosedis Nielsen J,Johannessen A,Raatikainen P,et al.Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.N Engl J Med,2012,367:1587-1595.
  • 3Tofield A.Study of ablation versus antiarrhythmic drugs in persistent atrial fibrillation study shows ablation superior to drugs for patients with persistent atrial fibrillation.Eur Heart J,2014,35:1164-1165.
  • 4Morillo CA,Verma A,Connolly SJ,et al.Radiofrequency ablation vs.antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation(RAAFT-2):a randomized trial.JAMA.2014;311:692-700.
  • 5Seitz J,Pisapia A,Beurtheret S.Catheter ablation for persistent atrial fibrillation.N Engl J Med,2015,373:878.
  • 6Scheinman MM,Huang S.The 1998 NASPE prospective catheter ablation registry.Pacing Clin Electrophysiol,2000,23:1020-1028.
  • 7Cappato R,Calkins H,Chen SA,et al.Worldwide survey on the methods,efficacy,and safety of catheter ablation for human atrial fibrillation.Circulation,2005,111:1100-1105.
  • 8Hunter RJ,Schilling RJ.Long-term outcome after catheter ablation for atrial fibrillation:safety,efficacy and impact on prognosis.Heart,2010,96:1259-1263.
  • 9Zhu W,He W,Guo L,et al.The HAS-BLED score for predicting major bleeding risk in anticoagulated patients with atrial fibrillation:a systematic review and Meta-analysis.Clin Cardiol,2015,38:555-561.
  • 10January CT,Wann LS,Alpert JS,et al.2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation:executive summary:a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.Circulation,2014,130:2071-2104.

引证文献11

二级引证文献84

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部